Last reviewed 2026-05-22 · How we verify

Neuromultivit

Bausch Health Americas, Inc. · Phase 3 active Small molecule ✓ Verified May 2026

Neuromultivit is a Small molecule drug developed by Bausch Health Americas, Inc.. It is currently in Phase 3 development.

Neuromultivit is being studied for the treatment of Vertebrogenic Radiculopathy L5, S1 in a clinical trial. The trial is comparing the safety and efficacy of Neuromultivit to Voltaren and Sirdalud.

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Neuromultivit
Sponsor	Bausch Health Americas, Inc.
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Neuromultivit CI brief — competitive landscape report
Neuromultivit updates RSS · CI watch RSS
Bausch Health Americas, Inc. portfolio CI

Frequently asked questions about Neuromultivit

What is Neuromultivit?

Neuromultivit is a Small molecule drug developed by Bausch Health Americas, Inc..

Who makes Neuromultivit?

Neuromultivit is developed by Bausch Health Americas, Inc. (see full Bausch Health Americas, Inc. pipeline at /company/bausch-health-americas-inc).

What development phase is Neuromultivit in?

Neuromultivit is in Phase 3.

Manufacturer: Bausch Health Americas, Inc. — full pipeline
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing